INTRODUCING A REVOLUTION IN CELL & GENE THERAPY

Despite enormous potential existing cell therapies have severe limitations. Current approaches rely on harvesting a patient’s own immune cells, expanding and genetically modifying them before reinfusion—a process that is lengthy, costly, and prone to failure. These challenges delay treatment and drive up costs for both patients and payers. 

Additionally, the single-chain CAR architecture commonly used in cell therapies can trigger tonic signaling, leading to cell exhaustion and eventual therapeutic failure. On top of that, weak activation signals often fail to fully engage the immune system for a robust response.